We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

13 hedge funds and large institutions have $5.17M invested in ProShares UltraShort NASDAQ Biotechnology in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

287% more capital invested

Capital invested by funds: $1.34M → $5.17M (+$3.83M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

30% more funds holding

Funds holding: 10 → 13 (+3)

1.06% more ownership

Funds ownership: 0% → 1.06% (+1.1%)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
–
Closed
5
Calls
$2.87M
Puts
–
Net Calls
+$2.87M
Net Calls Change
+$1.9M

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.33M
2
VF
Virtu Financial
New York
+$766K
3
HF
HRT Financial
New York
+$402K
4
Jane Street
Jane Street
New York
+$327K
5
FAM
Fred Alger Management
New York
+$239K

Top Sellers

Rank Fund Capital Flow
1
BPC
Banque Pictet & Cie
Switzerland
-$215K
2
USGIU
U.S. Global Investors (USGI)
Texas
-$79K
3
CG
Cutler Group
California
-$39.1K
4
FTUS
Flow Traders U.S.
New York
-$3K
5
HR
Howe & Rusling
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
1
Tower Research Capital (TRC)
New York
$1.57M +$1.33M +4,846 +625%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$908K +$115K +422 +15%
VF
3
Virtu Financial
New York
$784K +$766K +2,801 New
HF
4
HRT Financial
New York
$411K +$402K +1,469 New
Jane Street
5
Jane Street
New York
$334K +$327K +1,194 New
FAM
6
Fred Alger Management
New York
$245K +$239K +875 New
Citadel Advisors
7
Citadel Advisors
Florida
$233K +$228K +833 New
VKH
8
Virtu KCG Holdings
New York
$233K +$228K +833 New
Morgan Stanley
9
Morgan Stanley
New York
$196K +$173K +632 +943%
Simplex Trading
10
Simplex Trading
Illinois
$104K +$102K +372 New
UBS Group
11
UBS Group
Switzerland
$63K +$61.3K +224 New
Toronto Dominion Bank
12
Toronto Dominion Bank
Ontario, Canada
$49K – – –
Bank of America
13
Bank of America
North Carolina
$35K – – –
BPC
14
Banque Pictet & Cie
Switzerland
– -$215K -850 Closed
USGIU
15
U.S. Global Investors (USGI)
Texas
– -$79K -250 Closed
CG
16
Cutler Group
California
– -$39.1K -143 Closed
FTUS
17
Flow Traders U.S.
New York
– -$3K -13 Closed
HR
18
Howe & Rusling
New York
– -$2K -9 Closed

BIS Hedge Fund Activity: Q4 2016 in Review

13 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2016, worth a combined $5.17M — up 287% from $1.34M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BIS positions and 5 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $1.33M. The largest seller was Banque Pictet & Cie, exiting entirely with an estimated $215K sold.

  • 13 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2016, up from 10 in Q3 2016.
  • Funds reported $5.17M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2016, up 287% quarter-over-quarter.
  • 8 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2016 and 5 closed out, a net change of +3 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2016 was Tower Research Capital (TRC), an estimated $1.33M added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2016 was Banque Pictet & Cie, an estimated $215K sold.

Based on aggregated 13F filings for Q4 2016.